REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007
Thursday, August 3, 2006 BiopharmaWatch Research 1 min read
Key Takeaway: REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
REGENERON REPORTS SECOND QUARTER FINANCIAL AND OPERATING RESULTS BLA Filing for Auto-Inflammatory Diseases Planned for Early 2007 Two Antibody Candidates from VelocImmune Program to Enter Clinical Trials Each Year Beginning in 2007.